神经药理学报

神经药理学报 ›› 2026, Vol. 16 ›› Issue (2): 29-.DOI: 10.3969/j.issn.2095-1396.2026.02.004

• 研究论文 • 上一篇    下一篇

增强型体外反搏对心力衰竭合并认知障碍患者的疗效研究

刘加齐，李方江，秦少强，张爱爱，王子帅   

  1. 1. 河北北方学院研究生学院，张家口，075000，中国 

    2. 河北北方学院附属第一医院心血管内科，张家口，075000，中国

  • 出版日期:2026-04-30 发布日期:2026-06-16
  • 通讯作者: 李方江，教授，主任医师，硕士研究生导师；研究方向：心血管内科
  • 作者简介:刘加齐，在读硕士研究生；研究方向：心血管内科

Effect of Enhanced External Counterpulsation on Quality of Life, Cardiac Function, and Cognitive Function in Patients with Heart Failure and Cognitive Impairment

LIU Jia-qi, LI Fang-jiang, QIN Shao-qiang, ZHANG Ai-ai, WANG Zi-shuai   

  1. 1. Graduate School of Hebei North University, Zhangjiakou, 075000, China 

    2. Department of Cardiovascular Medicine, the First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, China

  • Online:2026-04-30 Published:2026-06-16

PDF (PC)

2

摘要：

目的：观察增强型体外反搏（enhanced external counterpulsation，EECP）对心力衰竭合并认知障碍患 者生活质量、心功能及认知功能的影响。方法：选取2024 年10 月—2025 年1 月就诊于河北北方学院附属第 一医院90 例心力衰竭合并认知障碍患者随机分为对照组和观察组各45 例，对照组给予心衰常规治疗，观察 组在此基础联合EECP。治疗7 周后比较两组明尼苏达心力衰竭生活质量问卷（Minnesota living with heart failure questionnaire，MLHFQ）、左室射血分数（left ventricular ejection fraction，LVEF）、6 分钟步行试验距离 （6-minute walking distance，6MWD）、舒张早期与晚期充盈速度比值（E/A 值）、纽约心功能分级（New York heart association，NYHA 分级）、左室舒张末期内径（left ventricular end-diastolic dimension，LVEDD）、N 末端脑钠肽前 体（N-terminal pro-B-type natriuretic peptide，NT-proBNP）、高敏C 反应蛋白（high-sensitivity C-reactive protein， hs-CRP）、30 天再住院率、日常生活活动能力（activities of daily living，ADL）量表评分、蒙特利尔认知评估量 表（Montreal cognitive assessment，MoCA）评分的差异。结果：治疗后，两组MLHFQ 评分均下降，观察组下降 更显著（P<0.05）。心功能方面，观察组LVEF、6MWD、E/A 值及NYHA 分级改善更优，LVEDD、NT-proBNP 及 hsCRP 下降幅度大于对照组（P<0.05），但两组30 天再住院率差异无统计学意义（P>0.05）。认知方面，观察组 MoCA 评分升高，ADL 评分改善优于对照组（P<0.05）；对照组MoCA 评分无显著变化。结论：EECP 有益于心力 衰竭合并认知障碍患者的生活质量、心功能及认知功能改善。

关键词: 增强型体外反搏, 心力衰竭, 认知障碍, 疗效评估

Abstract:

Objective: To observe the effects of enhanced external counterpulsation (EECP) on quality of life, cardiac function, and cognitive function in patients with heart failure complicated cognitive impairment. Methods: Ninety patients were randomly assigned to either a control group or an observation group, with 45 patients in each. The control group received standard heart failure treatment, while the observation group received EECP in addition to the standard treatment. After 7 weeks of treatment, comparisons were made between the two groups regarding the Minnesota living with heart failure questionnaire (MLHFQ) score, left ventricular ejection fraction (LVEF), 6-minute walking distance (6MWD), ratio of early to late diastolic ventricular filling velocities (E/A ratio), New York Heart Association (NYHA) functional classification, left ventricular end-diastolic dimension (LVEDD), N-terminal pro- B-type natriuretic peptide (NT-proBNP) levels, high-sensitivity C-reactive protein (hs-CRP) levels, 30-day readmission rate, activities of daily living (ADL) scale score, and Montreal cognitive assessment (MoCA) score. Results: After treatment, the MLHFQ scores decreased in both groups, with a more significant decrease observed in the EECP group (P<0.05). Regarding cardiac function, the EECP group showed superior improvement in LVEF, 6MWD, E/A ratio, and NYHA classification, as well as a greater reduction in LVEDD, NT-proBNP, and hs-CRP levels compared to the control group (P<0.05). However, no statistically significant difference was found in the 30-day readmission rate between the two groups (P>0.05). Regarding cognitive function, the MoCA scores increased and ADL scores improved more significantly in the EECP group compared to the control group (P<0.05); the control group showed no significant change in MoCA scores. Conclusion: EECP is beneficial for improving quality of life, cardiac function, and cognitive function in patients with heart failure complicated by cognitive impairment.

Key words: enhanced external counterpulsation, heart failure, cognitive impairment, therapeutic evaluation

中图分类号: